Establishment and characterization of a canine soft tissue sarcoma patient‐derived xenograft model

Spontaneously occurring soft tissue sarcoma (STS) is relatively common in canine cancer patients. Because of the similarities to human disease, canine STSs are a valuable and readily available resource for the study of new therapeutics. In this study, a canine patient‐derived xenograft (PDX) model,...

Full description

Saved in:

Bibliographic Details
Published in:	Veterinary & comparative oncology Vol. 15; no. 3; pp. 754 - 763
Main Authors:	Frazier, J. P., Beirne, E., Ditzler, S. H., Tretyak, I., Casalini, J. R., Thirstrup, D. J., Knoblaugh, S., Ward, J. G., Tripp, C. D., Klinghoffer, R. A.
Format:	Journal Article
Language:	English
Published:	Oxford, UK Blackwell Publishing Ltd 01-09-2017
Subjects:	Animals Antineoplastic Agents - therapeutic use Biomarkers, Tumor comparative oncology Disease Models, Animal Dogs Heterografts in vitro models Male Mice Mice, Nude mouse models Neoplasm Transplantation - methods Neoplasm Transplantation - veterinary oncology pathology Sarcoma - drug therapy Sarcoma - pathology Sarcoma - veterinary Sarcoma, Experimental - drug therapy Sarcoma, Experimental - pathology tumor biology mouse models tumor biology pathology in vitro models oncology comparative oncology
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Spontaneously occurring soft tissue sarcoma (STS) is relatively common in canine cancer patients. Because of the similarities to human disease, canine STSs are a valuable and readily available resource for the study of new therapeutics. In this study, a canine patient‐derived xenograft (PDX) model, CDX‐STS2, was established. The CDX‐STS2 model was engrafted and expanded for systemic administration studies with chemotherapeutic agents commonly used to treat STS, including doxorubicin, docetaxel and gemcitabine. Immunohistochemistry for drug‐specific biomarkers and tumour growth measurement revealed tumour sensitivity to doxorubicin and docetaxel, whereas gemcitabine had no effect on tumour growth. Although many human PDX tumour models have been established, relatively few canine PDX models have been reported to date. CDX‐STS2 represents a new STS PDX research model of canine origin that will be useful in bridging preclinical research with clinical studies of STS in pet dogs.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1476-5810 1476-5829
DOI:	10.1111/vco.12215